Remington-Davis, Inc., and Riverside Infection Consultants, Inc. — Columbus, Ohio

Remington-Davis, Inc., and Riverside Infection Consultants, Inc. is a clinical research site located in Columbus, Ohio, United States 43214.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Remington-Davis, Inc., and Riverside Infection Consultants, Inc. has participated in 1 clinical trials.

Therapeutic areas: Clostridium Difficile.

Sponsors: Romark Laboratories L.C..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Columbus

Browse all research sites in Ohio · View every site in Columbus

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Remington-Davis, Inc., and Riverside Infection Consultants, Inc.?

Remington-Davis, Inc., and Riverside Infection Consultants, Inc. has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Remington-Davis, Inc., and Riverside Infection Consultants, Inc. conducted?

Remington-Davis, Inc., and Riverside Infection Consultants, Inc. has 1 clinical trials on record. Their work covers Clostridium Difficile.

Is Remington-Davis, Inc., and Riverside Infection Consultants, Inc. accredited by Crixeo Clinical Trials?

Remington-Davis, Inc., and Riverside Infection Consultants, Inc. has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Remington-Davis, Inc., and Riverside Infection Consultants, Inc.?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.